4 unchanged sentences
Amended and Restated Bylaws
−Removed: Second Amendment to Clinical Trial and Option Agreement dated May 6, 2020 between Cancer Research UK, Cancer Research Technology Limited (“CRT”), Asterias Biotherapeutics, Inc.
−Removed: and Registrant.
−Removed: Agreement dated May 6, 2020 between CRT and Registrant
+Added: Lease Termination Agreement dated September 11, 2020
Certification of Chief Executive Officer pursuant to Form of Rule 13a-14(a), as Adopted Pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002
8 unchanged sentences
Taxonomy Extension Presentation Linkbase
+Added: Cover Page Interactive Data
+Added: File (embedded within the Inline XBRL document)
Filed herewith
Furnished herewith
−Removed: Portions of this exhibit have been omitted because the omitted information is:
−Removed: (i) not material;
−Removed: and (ii) would likely cause competitive
−Removed: harm to the registrant if publicly disclosed
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
1 unchanged sentence
CELL THERAPEUTICS, INC.
−Removed: August 6, 2020
+Added: November 4, 2020
Executive Officer
−Removed: August 6, 2020
+Added: November 4, 2020
Financial Officer
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.